PRO-C19
A fragment of the C-terminal domain of type XIX collagen, enabling non-invasive monitoring of basement membrane remodeling and extracellular matrix dynamics in oncology research.
Key features and values
- Quantifies C-terminal fragments of type XIX collagen associated with basement membrane remodeling.
- Reflects extracellular matrix dynamics in various cancer types, including non-small cell lung cancer.
- Provides a non-invasive measure of tumor microenvironment remodeling.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix components.
- Applicable in research on cancers characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The PRO-C19 biomarker assay measures specific fragments of the C-terminal domain of type XIX collagen, serving as an indicator of basement membrane remodeling and extracellular matrix dynamics in oncology research. This non-invasive assay provides insights into tissue remodeling processes associated with various cancer types, including non-small cell lung cancer. By quantifying type XIX collagen degradation products, the PRO-C19 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor microenvironment remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in cancer.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
